Multivessel Hybrid Revascularization for Three-Vessel CAD vs Conventional Off-Pump CABG
Official title: MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'
Run by Catharina Ziekenhuis Eindhoven · NCT07314138 · Data updated 2026-11-12
This trial tests whether a minimally invasive multivessel hybrid revascularization (LAD and circumflex grafted via a small thoracotomy plus PCI for the RCA) is better than traditional off-pump CABG done through sternotomy in people with three-vessel coronary disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Catharina Ziekenhuis Eindhoven Academic / other |
| Locations | 2 sites (Leuven, Vlaams Brabant and 1 other locations) |
| Status | Recruiting |
| Started | August 25, 2026 |
| Main results expected | May 1, 2029 |
| Study ends | May 1, 2034 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT07314138 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with three-vessel coronary disease eligible for complete revascularization, suitable for either multivessel-HCR or OPCAB.
✕Probably not a fit
Patients who do not meet inclusion criteria or have high-risk features that necessitate alternative strategies may not benefit from the hybrid approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter randomized trial enrolling patients with three-vessel coronary disease to compare multivessel hybrid coronary revascularization (MICS-based arterial grafting to the LAD and LCx, plus PCI to the RCA) against conventional off-pump CABG via median sternotomy. The primary endpoint is a 30-day Textbook Outcome, a composite of death, myocardial infarction, stroke, re-exploration for bleeding, and other major complications. The study aims to determine if the hybrid approach improves perioperative recovery and long-term cardiovascular outcomes while reducing surgical trauma. Enrollment targets 250 participants across participating centers. Outcomes will inform whether multivessel-HCR can be a preferred revascularization strategy for complex three-vessel disease.
Why it matters
Potential benefit: If successful, patients could experience shorter recovery, fewer complications, and comparable or better long-term heart outcomes with a less invasive approach.
How similar studies have gone: Prior studies suggest favorable short-term recovery with minimally invasive strategies, but multivessel-HCR in this exact configuration is being evaluated for its added value.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with three-vessel disease (either angiographic stenoses \>70% or a fractional flow reserve value ≤0.80) * Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery Exclusion Criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study: * Age \< 18 or \> 85 years * Chronic total occlusion of the RCA * In-stent RCA restenosis * RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation. * Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization. * Acute cardiac ischemia necessitating immediate intervention. * EF \< 30 % * eGFR \< 30 ml/min * Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery * Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest * Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer. * Hemodynamically significant left subclavian stenosis * Severe chest wall deformities * History of pericarditis * Body mass index \> 40 Kg/m2.
Where it's running
-
University Hospitals Leuven
Leuven, Vlaams Brabant, Belgium Recruiting -
Catharina Hospital Eindhoven
Eindhoven, Eindhoven, Netherlands Recruiting
Study contacts
- Principal investigator: Ferdi Akca, MD, PhD — Catharina Ziekenhuis Eindhoven
- Study coordinator: Ferdi Akca, MD, PhD
- Email: ferdi.akca@catharinaziekenhuis.nl
- Phone: +31 40 239 9111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD
This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.
-
Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD
This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.
-
Predicting Plaque Growth Using Blood Flow Stress Markers
This study tests whether combining blood flow patterns in the heart arteries with how blood-flow–sensitive cells respond can help predict which plaques will grow in people with coronary artery disease.
-
Identifying Coronary Plaque Traits with Photon-counting CT and Multimodality Imaging
This study tests whether advanced imaging can better identify risky artery plaques in people with stable angina.
-
Multimodal regional nerve blocks to improve recovery after off-pump CABG
This study tests whether using multiple regional nerve blocks can reduce pain and help patients recover after off-pump coronary artery bypass surgery.
-
Health for Hungary: Long-term blood and health data collection to study aging and disease onset
This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.